Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BLFS | Common Stock, par value $.001 per share | Other | +131K | +1.77% | 7.57M | Sep 1, 2021 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The reported securities were received by Casdin Partners Master Fund, L.P. (the "Master Fund") upon closing of the merger between Sexton Biotechnologies, Inc. ("Sexton") and the Issuer with approximately 10% of the amount deposited into an escrow account for indemnification and post-closing purchase price adjustments. The foregoing description of the merger does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on September 8, 2021, which is incorporated by reference. |
F2 | The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
The original Form 4 is being amended to update the beneficial ownership information reported therein. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.